Related Experiment Video
Updated: Jul 9, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Unlocking the EGFR-mediated epitranscriptome: A pathway to novel therapies
Jovanka Gencel-Augusto1, Trever G Bivona2
1Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94158, USA; UCSF Hellen Diller Comprehensive Cancer Center, San Francisco, CA 94158, USA.
None:
In this issue, Lv et al.1 explore EGFR-driven epitranscriptomic reprogramming in glioblastoma, revealing the pivotal role of the EGFR-ALKBH5-GCLM axis in ferroptosis protection. Their findings offer mechanistic insight and therapeutic strategies involving novel combination targets to enhance tumor responses.
More Related Videos
Related Concept Videos
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...

